TaiGen Biopharmaceuticals Holdings Limited Stock
Equities
4157
KYG866171005
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
15.45 TWD | -0.32% | +7.67% | +1.64% |
Sales 2022 | 36.23M 1.11M | Sales 2023 | 123M 3.77M | Capitalization | 10.91B 334M |
---|---|---|---|---|---|
Net income 2022 | -237M -7.26M | Net income 2023 | 137M 4.2M | EV / Sales 2022 | 294 x |
Net cash position 2022 | 860M 26.36M | Net cash position 2023 | 963M 29.52M | EV / Sales 2023 | 80.8 x |
P/E ratio 2022 |
-48.5
x | P/E ratio 2023 |
80
x | Employees | - |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 50% |
1 day | -0.32% | ||
1 week | +7.67% | ||
1 month | +3.69% | ||
3 months | +3.34% | ||
6 months | +3.69% | ||
Current year | +1.64% |
Managers | Title | Age | Since |
---|---|---|---|
Philip Huang
CEO | Chief Executive Officer | - | 18-12-16 |
Richard Lue
DFI | Director of Finance/CFO | - | 16-03-31 |
Ming-Chu Hsu
BRD | Director/Board Member | - | 01-03-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Shou-Chuan Ho
BRD | Director/Board Member | - | 13-04-28 |
Hong Jen Chang
BRD | Director/Board Member | 68 | 13-03-31 |
Sheng Fu Yu
BRD | Director/Board Member | 79 | 19-06-11 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.00% | 4 M€ | -4.41% | - | |
0.00% | 34 M€ | +2.35% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-25 | 15.5 | +0.32% | 1,956,406 |
24-04-24 | 15.45 | -0.32% | 3,644,589 |
24-04-23 | 15.5 | -0.64% | 3,939,570 |
24-04-22 | 15.6 | -5.17% | 13,097,220 |
24-04-19 | 16.45 | +4.44% | 26,229,620 |
End-of-day quote Taipei Exchange, April 23, 2024
More quotes1st Jan change | Capi. | |
---|---|---|
+1.64% | 340M | |
-3.16% | 104B | |
+0.03% | 97.42B | |
+1.40% | 22.2B | |
-18.33% | 21.23B | |
-10.95% | 18.33B | |
-42.83% | 16.35B | |
-17.04% | 15.06B | |
+3.55% | 13.98B | |
+28.65% | 11.66B |
- Stock Market
- Equities
- 4157 Stock